BioSpace News Archive

Dr. Suresh Neelagaru is opening the Lonestar Cardiovascular Center to bring quality care, cost savings, and convenience to the area

Clearside Biomedical, Inc. (NASDAQ:CLSD), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 11:30 a.m. ET.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at H.C. Wainwright 22nd Annual Global Investment Conference,

Quotient Limited, a commercial-stage diagnostics company, announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, announced that it has commenced an underwritten public offering of $350 million of shares of its common stock.

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401. FB-401, a live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa , was studied in an open-label Phase 1/2a trial in atopi

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Sav

Sonoma Pharmaceuticals and Te Arai BioFarma Announce Launch of Two New Microcyn ® Technology Products in Australia – Nasocyn ® Nasal Care and Oracyn ® Oral Care

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock in the aggregate, consisting of an offering of shares of common stock (the “

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept. 15, 2020, at 9:30 a.m. ET.